GLP-1 Action: Lupin For 2026 Launch, Aurobindo Too Eyes Semaglutide, Liraglutide

Denosumab Europe Launch In ’26, Says Aurobindo

 
• By Vibha Ravi

Indian firms Lupin and Aurobindo lay out global plans for GLP-1 agonists, as Aurobindo also updates on its biosimilar ambitions as they report results for fiscal Q2.

Image of semaglutide, liraglutide injections
Loss Of Exclusivity On Novo Nordisk's GLP-1 Products Is Keenly Awaited (Shutterstock)

More from India

More from Therapy Areas